XML 69 R59.htm IDEA: XBRL DOCUMENT
v3.20.2

Commitments and Contingencies (Details Textual) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Mar. 31, 2020 USD ($) | Feb. 28, 2020 USD ($) | Feb. 28, 2020 CNY (¥) | Feb. 24, 2020 USD ($) | Feb. 24, 2020 CNY (¥) | Aug. 29, 2019 USD ($) | Oct. 23, 2018 USD ($) | May 29, 2018 | Oct. 25, 2017 | Jun. 30, 2020 USD ($) | Jun. 30, 2019 USD ($) | Jun. 30, 2020 USD ($) | Jun. 30, 2019 USD ($) | Dec. 31, 2019 USD ($) | Oct. 23, 2018 CNY (¥)
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Joint venture agreement, description |  |  |  |  |  |  | Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed upon milestones. |  |  |  |  |  |  |  |
Research and development fee |  |  |  |  |  |  |  |  |  | $ 161,101 | $ 949,711 | $ 436,503 | $ 1,102,171 |  |
Line of Credit Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Line of credit |  |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |
Line of facility mature date |  |  |  |  |  | Dec. 31, 2024 |  |  |  |  |  |  |  |  |
Line of Credit bears interest at an annual rate |  |  |  |  |  | 5.00% |  |  |  |  |  |  |  |  |
Received Loan |  |  |  |  |  |  |  |  |  |  |  | 2,900,000 |  |  |
Avalon Shanghai [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Joint venture agreement, description |  |  |  |  |  |  |  | Avalon Shanghai entered into a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. ("Unicorn"), pursuant to which a company named Epicon Biotech Co., Ltd. ("Epicon") was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai. Within five years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000 (approximately $1.1 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon, and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.4 million). Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. As of June 30, 2020, Avalon Shanghai has contributed RMB 4,300,000 (approximately $0.6 million) that was included in equity method investment on the accompanying consolidated balance sheets. |  |  |  |  |  |  |
AVAR BioTherapeutics (China) Co. Ltd. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Joint venture agreement, description |  |  |  |  |  |  | Avactis Biosciences, Inc. ("Avactis"), a wholly-owned subsidiary of the Company, and Arbele Limited ("Arbele") agreed to the establishment of AVAR BioTherapeutics (China) Co. Ltd. ("AVAR"), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture Agreement (the "AVAR Agreement"), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy in China. Avactis is required to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis' cash reserves. Within 30 days, Arbele shall make a contribution of $6.66 million in the form of entering into a License Agreement with AVAR granting AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed upon Avactis and AVAR and services. |  |  |  |  |  |  |  |
Working capital |  |  |  |  |  |  | $ 700,000 |  |  |  |  |  |  |  |
Research and development fee |  |  |  |  |  |  |  |  |  |  |  | 900,000 |  |  |
RMB [Member] | AVAR BioTherapeutics (China) Co. Ltd. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Working capital | ¥ |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ¥ 5,000,000
Beijing Genexosome Office Lease [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expiration period |  | Apr. 14, 2021 | Apr. 14, 2021 |  |  |  |  |  |  |  |  |  |  |  |
Lease, total rent | $ 1,400 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease, monthly rent |  | $ 120 |  |  |  |  |  |  |  |  |  |  |  |  |
Rent expense | 328 |  |  |  |  |  |  |  |  |  |  | 383 |  |  |
Future minimum rental payment |  |  |  |  |  |  |  |  |  | 1,034 |  | 1,034 |  |  |
Security deposit |  | $ 700 |  |  |  |  |  |  |  |  |  |  |  |  |
Lease, description |  | The term of the lease is 13 months commencing on March 15, 2020 and expires on April 14, 2021 with one month of free rent. | The term of the lease is 13 months commencing on March 15, 2020 and expires on April 14, 2021 with one month of free rent. |  |  |  |  |  |  |  |  |  |  |  |
Operating lease |  |  |  |  |  |  |  |  |  |  |  | 62,185 |  |  |
Stock purchase agreement, description |  |  |  |  |  |  |  |  | Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr. Zhou and issued Dr. Zhou 400 shares of common stock of Genexosome. |  |  |  |  |  |
Beijing Genexosome Office Lease [Member] | RMB [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease, total rent | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease, monthly rent |  | $ 833 |  |  |  |  |  |  |  |  |  |  |  |  |
Security deposit | ¥ |  |  | ¥ 5,000 |  |  |  |  |  |  |  |  |  |  |  |
Avalon Shanghai Office Lease [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expiration period |  |  |  | Feb. 28, 2021 | Feb. 28, 2021 |  |  |  |  |  |  |  |  |  |
Lease, monthly rent |  |  |  | $ 7,000 |  |  |  |  |  |  |  |  |  |  |
Rent expense |  |  |  |  |  |  |  |  |  | 23,000 |  | 31,000 |  |  |
Security deposit |  |  |  | 23,000 |  |  |  |  |  |  |  |  |  |  |
Operating lease maintenance fees |  |  |  | $ 600 |  |  |  |  |  |  |  |  |  |  |
Lease, description |  |  |  | The term of the Beijing Office Lease is 12 months commencing on March 1, 2020 and expires on February 28, 2021. | The term of the Beijing Office Lease is 12 months commencing on March 1, 2020 and expires on February 28, 2021. |  |  |  |  |  |  |  |  |  |
Avalon Shanghai Office Lease [Member] | RMB [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease, monthly rent | ¥ |  |  |  |  | ¥ 50,586 |  |  |  |  |  |  |  |  |  |
Security deposit | ¥ |  |  |  |  | 164,764 |  |  |  |  |  |  |  |  |  |
Operating lease maintenance fees | ¥ |  |  |  |  | ¥ 4,336 |  |  |  |  |  |  |  |  |  |
New York Lease [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expiration period |  |  |  |  |  |  |  |  |  |  |  |  |  | Dec. 31, 2022 |
Lease, monthly rent |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,000 |
Rent expense |  |  |  |  |  |  |  |  |  | $ 18,000 |  | $ 36,000 |  |  |
Lease, description |  |  |  |  |  |  |  |  |  |  |  |  |  | The term of the New York Lease is 3 years commencing on January 1, 2020 and expires on December 31, 2022. |

X
- References No definition available. + Details
Name: | avco_CommitmentsAndContingenciesTextualAbstract
Namespace Prefix: | avco_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | avco_JointVentureAgreementDescription
Namespace Prefix: | avco_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of loans recevied. + References No definition available. + Details
Name: | avco_LoanRecevied
Namespace Prefix: | avco_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + References No definition available. + Details
Name: | avco_SecurityDeposits
Namespace Prefix: | avco_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Stock purchase agreement, description. + References No definition available. + Details
Name: | avco_StockPurchaseAgreementDescription
Namespace Prefix: | avco_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | avco_WorkingCapital
Namespace Prefix: | avco_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cost of maintenance incurred and directly related to good produced and service rendered. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_CostMaintenance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_DebtInstrumentMaturityDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Date which lease or group of leases is set to expire, in CCYY-MM-DD format. + References No definition available. + Details
Name: | us-gaap_LeaseExpirationDate1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of lessee's operating lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980 + Details
Name: | us-gaap_LesseeOperatingLeaseDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(16)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 + Details
Name: | us-gaap_LineOfCredit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The effective interest rate during the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_LineOfCreditFacilityInterestRateDuringPeriod
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 30 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 30 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121561866&loc=SL77919311-209978 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 6A -URI http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306 + Details
Name: | us-gaap_OperatingLeaseLeaseIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 55 -Paragraph 40 -Subparagraph (Note 3) -URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697 + Details
Name: | us-gaap_OperatingLeasesFutureMinimumPaymentsDue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717 + Details
Name: | us-gaap_OperatingLeasesRentExpenseNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The yearly payments due under the lease entered into in connection with the transaction involving the sale of property to another party and the lease of the property back to the seller. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694 Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121586228&loc=d3e50796-112755 + Details
Name: | us-gaap_SaleLeasebackTransactionAnnualRentalPayments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the monthly rental payments due under the lease entered into in connection with the transactions involving the sale of property to another party and the lease of the property back to the seller. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 40 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121586228&loc=d3e50796-112755 + Details
Name: | us-gaap_SaleLeasebackTransactionMonthlyRentalPayments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=avco_LineOfCreditAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AvalonShanghaiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AVARBioTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | avco_TypesOfCurrencyAxis=avco_RMBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=avco_BeijingGenExosomeOfficeLeaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=avco_AvalonShanghaiOfficeLeaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=avco_NewYorkLeaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |